Price$15.42+1.30 (+9.25%)
01:30 PM07:45 PM
News · 26 weeks45+75%
2026-01-182026-07-12
Mix2690d
- Other9(35%)
- Insider8(31%)
- SEC Filings8(31%)
- Analyst1(4%)
Latest news
25 items- INSIDERNew insider Volles Warren Karl claimed ownership of 248,212 shares (SEC Form 3)3 - Biohaven Ltd. (0001935979) (Issuer)
- SECBiohaven Ltd. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Biohaven Ltd. (0001935979) (Filer)
- PRBiohaven Announces Scientific Leadership TransitionsDavid Pirman, Ph.D. promoted to Executive Vice President and Head of DiscoveryBruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborationsWarren Volles, General Counsel and Chief Legal Officer, also designated an executive officerNEW HAVEN, Conn., July 9, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this role, Dr. Pirman will lead the Company's internal drug-discovery organ
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Biohaven Ltd.SCHEDULE 13G/A - Biohaven Ltd. (0001935979) (Subject)
- PRBiohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 ActivatorEnrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026Emerging opakalim focal epilepsy and idiopathic generalized epilepsy data presented at recent R&D Day reinforce evidence of target engagement, potential for efficacy, and differentiated tolerability profileIn the ongoing focal epilepsy open-label extension (OLE) study, 54% of participants on opakalim 75 mg once-daily achieved a ≥50% reduction in seizure frequency compared to pre-randomization baseline, with a markedly lower incidence of nervous system adverse events compared to approved and investigational ASMs High double-blind completion rates of ~95%, and high
- ANALYSTBiohaven downgraded by BofA Securities with a new price targetBofA Securities downgraded Biohaven from Neutral to Underperform and set a new price target of $11.00
- PRBiohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' DiseaseBHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a new class of precision immunology medicines that eliminate the disease-driving antibodies at the root of autoimmune disease.BHV-1300 targets the TSHR-IgG1 autoantibody that drives Graves' disease, not the thyroid gland itself. This is a fundamental shift from existing treatment approaches.Exclusively licensed from Yale University, Biohaven's BHV-1300's pivotal trial marks the vanguard of a broader platform: multiple next-generation MoDE and TRAP™ extracellular protein degraders advancing across the pipeline to address immunologic disease.NEW HAVEN, Conn., June 29, 2026 /PRNewswire/ -- Biohaven L
- PRBiohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and ImmunomodulationBHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addressing the bioenergetic and immunometabolic basis of systemic and central nervous system disorders First-in-human study initiated with dose escalation ongoing; preliminary data in healthy participants demonstrates favorable pharmacokinetics supporting convenient, once-daily dosing and well a tolerated profile at projected therapeutic exposuresPenetrates blood-brain barrier and reverses metabolic dysfunction with 3-fold improvement in glucose utilization in human, whole brain model (Bexorg BrainEx platform, physiologically reactivated brains from human donors); preferential metabolic rescue in Al
- SECBiohaven Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Biohaven Ltd. (0001935979) (Filer)
- PRBiohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA NephropathyBHV-1300 demonstrated deep, rapid, and sustained lowering of pathogenic TSHR autoantibodies (TSHR-IgG1) in patients with Graves' hyperthyroidism receiving 1000 mg SC weekly, with mean reductions in TSHR-IgG1exceeding >80% over the 12-week study.Participants with Graves' overt hyperthyroidism, confirmed by elevated baseline thyroid tests despite being treated with anti-thyroid drug therapy (ATD), experienced normalization of thyroid hormones within weeks; T4 normalization occurring at a median of 3 weeks and T3 at a median of 5 weeks after the first administration of BHV-1300.These preliminary patient data from an ongoing Phase 1b study highlight deep lowering of TSHR-IgG1 with BHV-1300 as a
- PRBiohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability ProfileIn a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), the median time to the second day with a generalized tonic-clonic seizure was 141 days in the opakalim 75 mg once-daily treatment group vs. 47 days in the placebo group, representing a 3-fold prolongation.In an ongoing open-label extension (OLE) study in focal epilepsy, an updated data analysis shows 54% of patients with focal epilepsy on opakalim 75 mg once-daily achieved a ≥50% reduction in seizure frequency over any consecutive six months of open-label treatment compared to pre-randomization baseline.A six-month update of opakalim compassionate use treatment in a Kv7-activation dependent pat
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Biohaven Ltd.SCHEDULE 13G/A - Biohaven Ltd. (0001935979) (Subject)
- SECBiohaven Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Biohaven Ltd. (0001935979) (Filer)
- SECSEC Form 424B5 filed by Biohaven Ltd.424B5 - Biohaven Ltd. (0001935979) (Filer)
- SECSEC Form S-3ASR filed by Biohaven Ltd.S-3ASR - Biohaven Ltd. (0001935979) (Filer)
- SECSEC Form 10-Q filed by Biohaven Ltd.10-Q - Biohaven Ltd. (0001935979) (Filer)
- SECBiohaven Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Biohaven Ltd. (0001935979) (Filer)
- SECBiohaven Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Biohaven Ltd. (0001935979) (Filer)
- PRBiohaven Reports Recent Business Developments and First Quarter 2026 Financial ResultsBiohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming Yale Innovation Summit on May 27, 2026.Advancement of high-value, late-stage priority programs:Pivotal epilepsy program with selective Kv7 ion channel activator, opakalim, with expected topline results in 2H 2026.Phase 2 obesity study with myostatin-activin pathway inhibitor, taldefgrobep alfa, completed enrollment and topline data expected in 2H 2026.TRAP™ and MoDE™ Degraders Advancing to Pivotal TrialsPivotal trials in both IgA nephropathy (IgAN) with Gd-IgA1 TRAP degrader, BHV-1400, and Graves' disease with IgG MoDE degrader, BHV-1300, expected to initiate by mid-year.Sustained progress acr
- INSIDERSEC Form 4 filed by Director Mehta Kishan4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by Director Bailey Gregory4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by Director Heffernan Michael Thomas4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by Director Antonijevic Irina4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by Director Childs John W4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by Director Hugin Robert J4 - Biohaven Ltd. (0001935979) (Issuer)
BHVN FAQ
7 questionsWhat does Biohaven Ltd. do?
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole...Where does BHVN stock trade?
Biohaven Ltd. (BHVN) is listed on NYSE.What sector and industry is BHVN in?
Biohaven Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Biohaven Ltd. go public?
Biohaven Ltd. (BHVN) completed its IPO in 2022.What are analysts saying about BHVN?
Biohaven Ltd. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Underperform with a $1100.00 price target on 2026-06-29. Recent price targets range from $900.00 to $2300.00.What companies are similar to BHVN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare BHVN side-by-side with any of them on Quantisnow.How can I track BHVN on Quantisnow?
Quantisnow aggregates Biohaven Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BHVN to receive live email and push alerts on every new disclosure.